These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 21563162

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhaled mannitol for cystic fibrosis.
    Nolan SJ, Thornton J, Murray CS, Dwyer T.
    Cochrane Database Syst Rev; 2015 Oct 09; (10):CD008649. PubMed ID: 26451533
    [Abstract] [Full Text] [Related]

  • 7. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ, Thornton J, Murray CS, Dwyer T.
    Cochrane Database Syst Rev; 2020 May 01; 5(5):CD008649. PubMed ID: 32358807
    [Abstract] [Full Text] [Related]

  • 8. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ, Thornton J, Murray CS, Dwyer T.
    Cochrane Database Syst Rev; 2018 Feb 09; 2(2):CD008649. PubMed ID: 29424930
    [Abstract] [Full Text] [Related]

  • 9. Timing of hypertonic saline inhalation for cystic fibrosis.
    Elkins M, Dentice R.
    Cochrane Database Syst Rev; 2020 Feb 28; 2(2):CD008816. PubMed ID: 32107770
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Timing of hypertonic saline inhalation for cystic fibrosis.
    Elkins M, Dentice R.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD008816. PubMed ID: 22336853
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial.
    Bishop JR, Erskine OJ, Middleton PG.
    J Physiother; 2011 Feb 15; 57(4):223-9. PubMed ID: 22093120
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR, Craib ML, Pasta DJ, Millar SJ, Morgan WJ, Konstan MW, Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
    Pediatr Pulmonol; 2018 Jan 15; 53(1):43-49. PubMed ID: 29064184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.